Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02109770
Other study ID # GSN014
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 2012
Est. completion date August 2019

Study information

Verified date August 2019
Source Natera, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to collect blood from families with a child who has been diagnosed with a chromosomal disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.


Description:

The primary purpose of this study is to collect family triads from families affected by a genetic or microdeletion/duplication (MD/D) syndrome to further develop non-invasive prenatal testing based on fetal DNA isolated from maternal blood. To assist with the development of the test, we will need to collect blood samples from women whose child was diagnosed with a genetic or MD/D syndrome, a blood sample from that child as well as a blood sample from their confirmed unaffected siblings. Since the test is based on Natera's Parental Supportâ„¢ technology, buccal or blood samples from the biological fathers will also be requested.

A recent abstract from a five year study on prenatal microarray testing revealed that 1.6% of women who present for routine prenatal indications have a positive microarray test. With the frequency of microdeletions and microduplications (MD/D) now known to be higher than previously thought, the field is likely to move toward offering invasive testing for microarray abnormalities to all pregnant women. Although non-invasive prenatal testing for aneuploidy is now clinically available, it has become clear that non-invasive prenatal testing for MD/D is equally important. However, access to these samples is made difficult as the standard of care for offering microarray analysis to all pregnant women will take time to come to fruition. We would like to develop this non-invasive as the standard of care so that less women will have to undergo invasive testing for the diagnosis of microarray abnormalities. Thus, there is an unmet need for the development of novel tests that would increase the scope of non-invasive prenatal screening.


Recruitment information / eligibility

Status Completed
Enrollment 216
Est. completion date August 2019
Est. primary completion date June 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Couples who have a child diagnosed with an autosomal chromosome abnormality (e.g. Down syndrome, Edwards syndrome, Patau syndrome).

- Couples who have a child diagnosed with a sex chromosome abnormality (e.g. Turner syndrome, Klinefelter syndrome, Triple X syndrome, 47, XYY).

- Couples who have a child diagnosed with a microdeletion/duplication syndrome (a positive microarray test).

Exclusion criteria:

- Not an English language or Spanish language speaker

- Genetics report is not available

Study Design


Locations

Country Name City State
United States Children's Hospital Of Philadelphia Philadelphia Pennsylvania
United States Natera San Carlos California

Sponsors (1)

Lead Sponsor Collaborator
Natera, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Wapner RJ, Babiarz JE, Levy B, Stosic M, Zimmermann B, Sigurjonsson S, Wayham N, Ryan A, Banjevic M, Lacroute P, Hu J, Hall MP, Demko Z, Siddiqui A, Rabinowitz M, Gross SJ, Hill M, Benn P. Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am J Obstet Gynecol. 2015 Mar;212(3):332.e1-9. doi: 10.1016/j.ajog.2014.11.041. Epub 2014 Dec 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity and Specificity of the test to diagnose chromosomal microdeletions and aneuploidy in a fetus 4 years
See also
  Status Clinical Trial Phase
Completed NCT01925742 - Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood N/A
Completed NCT01852708 - Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood
Recruiting NCT05527652 - Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia N/A
Completed NCT02278536 - Multiple Gestation Study
Completed NCT01511458 - Non-invasive Chromosomal Examination of Trisomy Study N/A
Not yet recruiting NCT05970965 - Periodontitis and Inflammation in Children With Down Syndrome/Trisomy 21: Study on Biological Samples N/A
Terminated NCT03551418 - Learning by Repetitive Viewing of Peer Modeling Patient Education Videos by Adults With Down Syndrome N/A
Completed NCT01966991 - Prenatal Screening for Down Syndrome With DNAFirst N/A
Enrolling by invitation NCT03559374 - Study of Vanadis® NIPT for Non-invasive Prenatal Screening of Trisomies (T21, T18 and T13)
Active, not recruiting NCT01725438 - Non Invasive Prenatal Diagnosis of Trisomy 21 by Genetic Analysis of Circulating Fetal Cells N/A
Active, not recruiting NCT05981521 - Paternal Age and Fetal Aneuploidy
Completed NCT05004337 - Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies
Recruiting NCT02864108 - The Crnic Institute Human Trisome Project Biobank
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Not yet recruiting NCT06200519 - Assessment of Diastolic Function During the Transitional Period and Infancy Using Serial Echocardiography
Terminated NCT03687866 - Non-invasive Screening of Fetal Trisomy 21 by Digital PCR
Terminated NCT01545674 - Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial
Terminated NCT04747275 - Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients Phase 4
Completed NCT01821300 - Down Syndrome Metabolic Health Study
Completed NCT00877292 - A New Prenatal Blood Test for Down Syndrome N/A